Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With <i>ALK</i>-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study
Benjamin Solomon(Peter MacCallum Cancer Centre), Tony Mok(Chinese University of Hong Kong), Alessandra Bearz(Centro di Riferimento Oncologico), Óscar Arrieta(Instituto Nacional de Cancerología), Todd M. Bauer(Tennessee Oncology), Hidetoshi Hayashi(Kindai University), Anna Maria Calella(Pfizer (United States)), Konstantin Penkov, Gerson Peltz(Tennessee Oncology), Anna Polli(Pfizer (Italy)), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Jacek Jassem(Gdańsk Medical University), Geoffrey Liu(Princess Margaret Cancer Centre), Holger Thurm(Pfizer (United States))
Cited by 133
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k